Literature DB >> 29987617

How Long of a Dynamic 3'-Deoxy-3'-[18F]fluorothymidine ([18F]FLT) PET Acquisition Is Needed for Robust Kinetic Analysis in Breast Cancer?

Jun Zhang1, Xiaoli Liu1, Michelle I Knopp1, Bhuvaneswari Ramaswamy2, Michael V Knopp3.   

Abstract

PURPOSE: To quantitatively evaluate the minimally required scanning time of 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) positron emission tomography (PET) dynamic acquisition for accurate kinetic assessment of the proliferation in breast cancer tumors. PROCEDURES: Within a therapeutic intervention trial, 26 breast tumors of 8 breast cancer patients were analyzed from 30-min dynamic [18F]FLT-PET acquisitions. PET/CT was acquired on a Gemini TF 64 system (Philips Healthcare) and reconstructed into 26 frames (8 × 15 s, 6 × 30 s, 5 × 1 min, 5 × 2 min, and 2 × 5 min). Maximum activity concentrations (Bq/ml) of volume of interests over tumors and plasma in descending aorta were obtained over time frames. Kinetic parameters were estimated using in-house developed software with the two-tissue three-compartment irreversible model (2TCM) (K1, k2, k3, and Ki; k4 = 0) and Patlak model (Ki) based on different acquisition durations (Td) (10, 12, 14, 16, 20, 25, and 30 min, separately). Different linear regression onset time (T0) points (1, 2, 3, 4, and 5 min) were applied in Patlak analysis. Ki of the 30-min data set was taken as the gold standard for comparison. Pearson product-moment correlation coefficient (R) of 0.9 was chosen as a limit for the correlation.
RESULTS: The correlation of kinetic parameters between the gold standard and the abbreviated dynamic data series increased with longer Td from 10 to 30 min. k2 and k3 using 2TCM and Ki using Patlak model revealed poor correlations for dynamic PET with Td ≤ 14 min (k2: R = 0.84, 0.85, 0.86; k3: R = 0.67, 0.67, 0.67; Ki: R = 0.72, 0.78, 0.87 at Td = 10, 12, and 14 min, respectively). Excellent correlations were shown for all kinetic parameters when Td ≥ 16 min regardless of the kinetic model and T0 value (R > 0.9).
CONCLUSIONS: This study indicates that a 16-min dynamic PET acquisition appears to be sufficient to provide accurate [18F]FLT kinetics to quantitatively assess the proliferation in breast cancer lesions.

Entities:  

Keywords:  3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT); Acquisition duration; Breast Cancer; Dynamic PET; Kinetic modeling

Mesh:

Substances:

Year:  2019        PMID: 29987617      PMCID: PMC7201384          DOI: 10.1007/s11307-018-1231-x

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  33 in total

1.  A simplified analysis of [18F]3'-deoxy-3'-fluorothymidine metabolism and retention.

Authors:  Anthony F Shields; David A Briston; Samatha Chandupatla; Kirk A Douglas; Jawana Lawhorn-Crews; Jerry M Collins; Thomas J Mangner; Lance K Heilbrun; Otto Muzik
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-01       Impact factor: 9.236

2.  Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.

Authors:  Kuruva Manohar; Bhagwant Rai Mittal; Raja Senthil; Raghava Kashyap; Anish Bhattacharya; Gurpreet Singh
Journal:  Nucl Med Commun       Date:  2012-06       Impact factor: 1.690

3.  Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.

Authors:  David A Mankoff; Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Aaron Charlop; Thomas J Lawton; Erin K Schubert; Jeffrey Tseng; Robert B Livingston
Journal:  J Nucl Med       Date:  2002-04       Impact factor: 10.057

4.  Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.

Authors:  Nanda C Krak; Jacobus J M van der Hoeven; Otto S Hoekstra; Jos W R Twisk; Elsken van der Wall; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-15       Impact factor: 9.236

Review 5.  Positron Emission Tomography (PET) and breast cancer in clinical practice.

Authors:  Robert Lavayssière; Anne-Elizabeth Cabée; Jean-Emmanuel Filmont
Journal:  Eur J Radiol       Date:  2008-09-23       Impact factor: 3.528

Review 6.  A systematic review of FDG-PET in breast cancer.

Authors:  S Escalona; J A Blasco; M M Reza; E Andradas; N Gómez
Journal:  Med Oncol       Date:  2009-03-11       Impact factor: 3.064

Review 7.  Molecular imaging of breast cancer.

Authors:  T H Oude Munnink; W B Nagengast; A H Brouwers; C P Schröder; G A Hospers; M N Lub-de Hooge; E van der Wall; P J van Diest; E G E de Vries
Journal:  Breast       Date:  2009-10       Impact factor: 4.380

8.  Parametric Method Performance for Dynamic 3'-Deoxy-3'-18F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Carcinoma Patients Before and During Therapy.

Authors:  Gerbrand Maria Kramer; Virginie Frings; Dennis Heijtel; E F Smit; Otto S Hoekstra; Ronald Boellaard
Journal:  J Nucl Med       Date:  2016-11-10       Impact factor: 10.057

9.  Comparative functional evaluation of immunocompetent mouse breast cancer models established from PyMT-tumors using small animal PET with [(18)F]FDG and [(18)F]FLT.

Authors:  Alan Desilva; Melinda Wuest; Monica Wang; Jeff Hummel; Karen Mossman; Frank Wuest; Mary M Hitt
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

Review 10.  Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients.

Authors:  Antonia Dimitrakopoulou-Strauss; Leyun Pan; Ludwig G Strauss
Journal:  Cancer Imaging       Date:  2012-09-28       Impact factor: 3.909

View more
  1 in total

1.  Technical note: Partitioning of gated single photon emission computed tomography raw data for protocols optimization.

Authors:  Cleiton Cavalcante Queiroz; Marcos Antonio Dorea Machado; Antonio Augusto Brito Ximenes; Andre Gustavo Silva Pino; Eduardo Martins Netto
Journal:  J Appl Clin Med Phys       Date:  2021-12-17       Impact factor: 2.102

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.